{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Opdivo+Injectable+Product&page=2", "query": { "intervention": "Opdivo Injectable Product", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Opdivo+Injectable+Product&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-24T08:55:23.954Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03886311", "title": "Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC]", "type": "DRUG" }, { "name": "Nivolumab IV Soln 100 MG/10ML", "type": "DRUG" }, { "name": "Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sarcoma Oncology Research Center, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2019-05-15", "completion_date": "2031-07-31", "has_results": false, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-09-24T08:55:23.954Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03886311" }, { "nct_id": "NCT02831933", "title": "Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Squamous Cell Carcinoma Stage IV", "Nonsquamous Nonsmall Cell Neoplasm of Lung", "Metastatic Uveal Melanoma" ], "interventions": [ { "name": "ADV/HSV-tk", "type": "BIOLOGICAL" }, { "name": "Valacyclovir", "type": "DRUG" }, { "name": "SBRT", "type": "RADIATION" }, { "name": "nivolumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Eric Bernicker, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2017-02-15", "completion_date": "2020-11-05", "has_results": true, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-09-24T08:55:23.954Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02831933" }, { "nct_id": "NCT03432741", "title": "Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Adenocarcinoma", "Metastatic Breast Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Hodgkin Lymphoma", "Recurrent Mycosis Fungoides", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Refractory Breast Carcinoma", "Refractory Hodgkin Lymphoma", "Refractory Mycosis Fungoides", "Refractory Nodal Marginal Zone Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Stage IV Breast Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Belinostat", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Copanlisib Hydrochloride", "type": "DRUG" }, { "name": "Daratumumab", "type": "BIOLOGICAL" }, { "name": "Fludeoxyglucose F-18", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Romidepsin", "type": "DRUG" }, { "name": "Saline", "type": "OTHER" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2018-03-27", "completion_date": "2022-10-03", "has_results": false, "last_update_posted_date": "2025-05-26", "last_synced_at": "2026-09-24T08:55:23.954Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03432741" }, { "nct_id": "NCT03554317", "title": "COMbination of Bipolar Androgen Therapy and Nivolumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-resistant Prostate Cancer", "Metastatic Prostate Cancer", "Prostate Cancer" ], "interventions": [ { "name": "Testosterone cypionate", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 45, "start_date": "2018-09-05", "completion_date": "2023-01-06", "has_results": true, "last_update_posted_date": "2024-02-20", "last_synced_at": "2026-09-24T08:55:23.954Z", "location_count": 3, "location_summary": "San Francisco, California • Baltimore, Maryland • Boston, Massachusetts", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03554317" }, { "nct_id": "NCT05428007", "title": "Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Unresectable Melanoma" ], "interventions": [ { "name": "Sarilumab", "type": "DRUG" }, { "name": "Ipilimumab Injection", "type": "DRUG" }, { "name": "Nivolumab/Relatlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 105, "start_date": "2023-02-02", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-01-05", "last_synced_at": "2026-09-24T08:55:23.954Z", "location_count": 4, "location_summary": "Los Angeles, California • Boston, Massachusetts • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05428007" }, { "nct_id": "NCT03056599", "title": "Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Soft Tissue Sarcoma Adult" ], "interventions": [ { "name": "Multiple drug microinjection", "type": "DRUG" }, { "name": "CIVO device", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Presage Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2016-12-15", "completion_date": "2021-09-22", "has_results": false, "last_update_posted_date": "2021-09-24", "last_synced_at": "2026-09-24T08:55:23.954Z", "location_count": 3, "location_summary": "Lake Success, New York • Portland, Oregon • Seattle, Washington", "locations": [ { "city": "Lake Success", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03056599" }, { "nct_id": "NCT03121677", "title": "Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Follicular Lymphoma" ], "interventions": [ { "name": "Personalized tumor vaccine", "type": "BIOLOGICAL" }, { "name": "Poly ICLC", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Peripheral blood draws", "type": "PROCEDURE" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2018-10-16", "completion_date": "2023-08-07", "has_results": false, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-09-24T08:55:23.954Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03121677" }, { "nct_id": "NCT03353675", "title": "A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer Metastatic" ], "interventions": [ { "name": "TG4010", "type": "BIOLOGICAL" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Transgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2018-01-05", "completion_date": "2021-02-17", "has_results": true, "last_update_posted_date": "2022-01-11", "last_synced_at": "2026-09-24T08:55:23.954Z", "location_count": 2, "location_summary": "Charlotte, North Carolina • Nashville, Tennessee", "locations": [ { "city": "Charlotte", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03353675" }, { "nct_id": "NCT07430202", "title": "A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))" ], "interventions": [ { "name": "DNAJB1-PRKACA Peptide Vaccine", "type": "DRUG" }, { "name": "DRP-104", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 27, "start_date": "2026-09", "completion_date": "2030-09", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-24T08:55:23.954Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07430202" }, { "nct_id": "NCT03259867", "title": "Combination of TATE and PD-1 Inhibitor in Liver Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma", "Gastric Cancer" ], "interventions": [ { "name": "Nivolumab Injectable Product", "type": "DRUG" }, { "name": "Trans-arterial tirapazamine embolization", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Teclison Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 54, "start_date": "2017-07-01", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-09-24T08:55:23.954Z", "location_count": 3, "location_summary": "Orange, California • Oklahoma City, Oklahoma • Milwaukee, Wisconsin", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03259867" } ] }